Premium
OnabotulinumtoxinA for the Treatment of Poststroke Distal Lower Limb Spasticity: A Randomized Trial
Author(s) -
Wein Theodore,
Esquenazi Alberto,
Jost Wolfgang H.,
Ward Anthony B.,
Pan Grace,
Dimitrova Rozalina
Publication year - 2018
Publication title -
pmandr
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.617
H-Index - 66
eISSN - 1934-1563
pISSN - 1934-1482
DOI - 10.1016/j.pmrj.2017.12.006
Subject(s) - medicine , placebo , ankle , physical therapy , modified ashworth scale , spasticity , clinical endpoint , stroke (engine) , randomized controlled trial , clinical trial , physical medicine and rehabilitation , surgery , mechanical engineering , alternative medicine , pathology , engineering
Background Poststroke distal lower limb spasticity impairs mobility, limiting activities of daily living and requiring additional caregiver time. Objective To evaluate the efficacy, safety, and sustained benefit of onabotulinumtoxinA in adults with poststroke lower limb spasticity (PSLLS). Design A multicenter, randomized, double‐blind, phase 3, placebo‐controlled trial ( NCT01575054 ). Setting Sixty study centers across North America, Europe, Russia, the United Kingdom, and South Korea. Patients Adult patients (18‐65 years of age) with PSLLS (Modified Ashworth Scale [MAS] ≥3) of the ankle plantar flexors and the most recent stroke ≥3 months before study enrollment. Interventions During the open‐label phase, patients received ≤3 onabotulinumtoxinA treatments (≤400 U) or placebo at approximately 12‐week intervals. Treatments were into the ankle plantar flexors (onabotulinumtoxinA 300 U into ankle plantar flexors; ≤100 U, optional lower limb muscles). Main Outcome Measurements The double‐blind primary endpoint was MAS change from baseline (average score at weeks 4 and 6). Secondary measures included physician‐assessed Clinical Global Impression of Change (CGI), MAS change from baseline in optional muscles, Goal Attainment Scale (GAS), and pain scale. Results Of 468 patients enrolled, 450 (96%) completed the double‐blind phase and 413 (88%) completed the study. Small improvements in MAS observed with onabotulinumtoxinA during the double‐blind phase (onabotulinumtoxinA, –0.8; placebo, –0.6, P = .01) were further enhanced with additional treatments through week 6 of the third open‐label treatment cycle (onabotulinumtoxinA/onabotulinumtoxinA, –1.2; placebo/onabotulinumtoxinA, –1.4). Small improvements in CGI observed during the double‐blind phase (onabotulinumtoxinA, 0.9; placebo, 0.7, P = .01) were also further enhanced through week 6 of the third open‐label treatment cycle (onabotulinumtoxinA/onabotulinumtoxinA, 1.6; placebo/onabotulinumtoxinA, 1.6). Physician‐ and patient‐assessed GAS scores improved with each subsequent treatment. No new safety signals emerged. Conclusions OnabotulinumtoxinA significantly improved ankle MAS, CGI, and GAS scores compared with placebo; improvements were consistent and increased with repeated treatments of onabotulinumtoxinA over 1 year in patients with PSLLS. Level of Evidence I